Xilio Therapeutics (XLO) Competitors $0.84 -0.06 (-7.04%) Closing price 04:00 PM EasternExtended Trading$0.84 +0.01 (+1.20%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO vs. PBYI, KRRO, LFVN, SLS, FTLF, NKTX, CYBN, TNGX, NLTX, and EPRXShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Puma Biotechnology (PBYI), Korro Bio (KRRO), LifeVantage (LFVN), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), Tango Therapeutics (TNGX), Neoleukin Therapeutics (NLTX), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Puma Biotechnology Korro Bio LifeVantage SELLAS Life Sciences Group FitLife Brands Nkarta Cybin Tango Therapeutics Neoleukin Therapeutics Eupraxia Pharmaceuticals Xilio Therapeutics (NASDAQ:XLO) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation, risk and community ranking. Do insiders and institutionals have more ownership in XLO or PBYI? 54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Comparatively, 23.7% of Puma Biotechnology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer XLO or PBYI? In the previous week, Puma Biotechnology had 2 more articles in the media than Xilio Therapeutics. MarketBeat recorded 2 mentions for Puma Biotechnology and 0 mentions for Xilio Therapeutics. Puma Biotechnology's average media sentiment score of 0.54 beat Xilio Therapeutics' score of 0.00 indicating that Puma Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Xilio Therapeutics Neutral Puma Biotechnology Positive Which has better valuation & earnings, XLO or PBYI? Puma Biotechnology has higher revenue and earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Puma Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXilio Therapeutics$9.27M4.66-$76.40M-$0.84-0.99Puma Biotechnology$232.71M0.71$21.59M$0.774.35 Do analysts prefer XLO or PBYI? Xilio Therapeutics currently has a consensus price target of $4.00, suggesting a potential upside of 379.04%. Puma Biotechnology has a consensus price target of $7.00, suggesting a potential upside of 108.96%. Given Xilio Therapeutics' higher possible upside, equities research analysts plainly believe Xilio Therapeutics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Puma Biotechnology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is XLO or PBYI more profitable? Puma Biotechnology has a net margin of 9.56% compared to Xilio Therapeutics' net margin of 0.00%. Puma Biotechnology's return on equity of 41.60% beat Xilio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xilio TherapeuticsN/A -211.50% -80.31% Puma Biotechnology 9.56%41.60%10.71% Which has more volatility and risk, XLO or PBYI? Xilio Therapeutics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Does the MarketBeat Community prefer XLO or PBYI? Puma Biotechnology received 546 more outperform votes than Xilio Therapeutics when rated by MarketBeat users. However, 75.00% of users gave Xilio Therapeutics an outperform vote while only 67.39% of users gave Puma Biotechnology an outperform vote. CompanyUnderperformOutperformXilio TherapeuticsOutperform Votes1275.00% Underperform Votes425.00% Puma BiotechnologyOutperform Votes55867.39% Underperform Votes27032.61% SummaryPuma Biotechnology beats Xilio Therapeutics on 13 of the 16 factors compared between the two stocks. Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$43.24M$6.52B$5.37B$8.38BDividend YieldN/A2.65%5.22%4.11%P/E Ratio-0.498.9226.8419.71Price / Sales4.66253.80392.34117.39Price / CashN/A65.8538.2534.62Price / Book0.626.466.794.50Net Income-$76.40M$143.98M$3.23B$248.18M7 Day Performance-1.76%3.04%4.07%1.14%1 Month Performance2.45%7.44%12.52%15.20%1 Year Performance-30.42%-2.46%16.83%6.56% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics2.6401 of 5 stars$0.84-7.0%$4.00+379.0%-28.1%$43.24M$9.27M-0.4970PBYIPuma Biotechnology3.5529 of 5 stars$3.04+4.5%$7.00+130.3%-16.9%$150.88M$230.47M6.33200KRROKorro Bio1.9902 of 5 stars$15.98+2.7%$112.75+605.6%-70.4%$150.07M$2.27M-1.6970Analyst RevisionGap DownLFVNLifeVantage3.9893 of 5 stars$11.86-3.3%$30.50+157.2%+84.5%$149.29M$222.35M21.18260Gap DownSLSSELLAS Life Sciences Group0.3176 of 5 stars$1.54-1.3%N/A+31.1%$145.60M$1M-2.2310Gap UpFTLFFitLife Brands4.4273 of 5 stars$15.41-1.9%$20.50+33.0%+0.9%$144.61M$64.47M18.2420Earnings ReportNKTXNkarta1.9701 of 5 stars$2.02+4.7%$14.83+634.3%-73.3%$143.34MN/A-1.07140News CoveragePositive NewsEarnings ReportAnalyst RevisionGap UpCYBNCybin2.7205 of 5 stars$6.62-6.1%$86.00+1,199.1%N/A$142.18MN/A-1.5150News CoverageTNGXTango Therapeutics1.5872 of 5 stars$1.31+14.9%$12.33+841.5%-73.0%$141.62M$42.07M-1.1190NLTXNeoleukin TherapeuticsN/A$14.73-1.8%N/A-42.6%$138.43MN/A-4.7490Gap UpHigh Trading VolumeEPRXEupraxia Pharmaceuticals2.2192 of 5 stars$3.86+1.4%$10.50+172.4%+32.2%$138.20MN/A-5.3529Gap Up Related Companies and Tools Related Companies PBYI Competitors KRRO Competitors LFVN Competitors SLS Competitors FTLF Competitors NKTX Competitors CYBN Competitors TNGX Competitors NLTX Competitors EPRX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XLO) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
